Company History

  • January 2014

    China Biologic repurchased 2,500,000 shares of common stock from one of its individual shareholders for a consideration of $70,000,000.
  • October 2013

    Forbes magazine again named China Biologic to its annual list of Asia’s “200 Best Under a Billion.
  • August 2013

    China Biologic repurchased 1,479,704 shares of common stock from one of its individual shareholders for a consideration of $29,594,080.
  • July 2013

    Guizhou Taibang received manufacturing approval certificate for Human Prothrombin Complex Concentrate ("PCC") from China Food and Drug Administration (“CFDA”).
FirstPage | PreviousPage | NextPage | LastPage CurrentPageIndex:5 [1] [2] [3] [4] [5] [6] [7] [8] [9] 
© 2017 China Biologic Products Holdings, Inc. All Rights Reserved.